Literature DB >> 24859989

The social network of PELP1 and its implications in breast and prostate cancers.

Vijay K Gonugunta1, Lu Miao1, Gangadhara R Sareddy1, Preethi Ravindranathan1, Ratna Vadlamudi1, Ganesh V Raj2.   

Abstract

Proline, glutamic acid- and leucine-rich protein 1 (PELP1) is a multi-domain scaffold protein that serves as a platform for various protein-protein interactions between steroid receptors (SRs) and signaling factors and cell cycle, transcriptional, cytoskeletal, and epigenetic remodelers. PELP1 is known to be a coregulator of transcription and participates in the nuclear and extranuclear functions of SRs, ribosome biogenesis, and cell cycle progression. The expression and localization of PELP1 are dysregulated in hormonal cancers including breast and prostate cancers. This review focuses on the interactive functions and therapeutic and prognostic significance of PELP1 in breast and prostate cancers.
© 2014 Society for Endocrinology.

Entities:  

Keywords:  PELP1; coregulator; epigenetics; genomic signaling; hormonal cancers; interactome; network; nongenomic signaling; steroid receptors

Mesh:

Substances:

Year:  2014        PMID: 24859989     DOI: 10.1530/ERC-13-0502

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  9 in total

1.  PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.

Authors:  Yiliao Luo; Mengxing Li; Uday P Pratap; Suryavathi Viswanadhapalli; Junhao Liu; Prabhakar P Venkata; Kristin A Altwegg; Bridgitte E Palacios; Xiaonan Li; Yihong Chen; Manjeet K Rao; Andrew J Brenner; Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Mol Carcinog       Date:  2019-12-24       Impact factor: 4.784

Review 2.  Minireview: Deciphering the Cellular Functions of PELP1.

Authors:  Preethi Ravindranathan; Carol A Lange; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2015-07-09

3.  Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.

Authors:  Samaya R Krishnan; Binoj C Nair; Gangadhara R Sareddy; Sudipa Saha Roy; Mohan Natarajan; Takayoshi Suzuki; Yan Peng; Ganesh Raj; Ratna K Vadlamudi
Journal:  Breast Cancer Res Treat       Date:  2015-03-19       Impact factor: 4.872

Review 4.  PELP1: a key mediator of oestrogen signalling and actions in the brain.

Authors:  R Thakkar; G R Sareddy; Q Zhang; R Wang; R K Vadlamudi; D Brann
Journal:  J Neuroendocrinol       Date:  2018-02       Impact factor: 3.627

5.  Proline-, glutamic acid-, and leucine-rich protein 1 mediates estrogen rapid signaling and neuroprotection in the brain.

Authors:  Gangadhara R Sareddy; Quanguang Zhang; Ruimin Wang; Erin Scott; Yi Zou; Jason C O'Connor; Yidong Chen; Yan Dong; Ratna K Vadlamudi; Darrell Brann
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

Review 6.  PELP1: Structure, biological function and clinical significance.

Authors:  Gangadhara Reddy Sareddy; Ratna K Vadlamudi
Journal:  Gene       Date:  2016-03-18       Impact factor: 3.688

7.  Increased expression of PELP1 in human sperm is correlated with decreased semen quality.

Authors:  Izabela Skibinska; Miroslaw Andrusiewicz; Michal Soin; Magdalena Jendraszak; Paulina Urbaniak; Piotr Jedrzejczak; Malgorzata Kotwicka
Journal:  Asian J Androl       Date:  2018 Sep-Oct       Impact factor: 3.285

8.  PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling.

Authors:  Gangadhara R Sareddy; Uday P Pratap; Suryavathi Viswanadhapalli; Prabhakar Pitta Venkata; Binoj C Nair; Samaya Rajeshwari Krishnan; Siyuan Zheng; Andrea R Gilbert; Andrew J Brenner; Darrell W Brann; Ratna K Vadlamudi
Journal:  Neurooncol Adv       Date:  2019-11-05

9.  EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities.

Authors:  Ozlem Yedier-Bayram; Bengul Gokbayrak; Alisan Kayabolen; Ali Cenk Aksu; Ayse Derya Cavga; Ahmet Cingöz; Ezgi Yagmur Kala; Goktug Karabiyik; Rauf Günsay; Beril Esin; Tunc Morova; Fırat Uyulur; Hamzah Syed; Martin Philpott; Adam P Cribbs; Sonia H Y Kung; Nathan A Lack; Tamer T Onder; Tugba Bagci-Onder
Journal:  Cell Death Dis       Date:  2022-08-16       Impact factor: 9.685

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.